

5th International Conference on

Clinical & Experimental Ophthalmology

August 04-06, 2015 Valencia, Spain

Plasma rich in growth factors in eye drops for the treatment of ocular surface disease in patients with glaucoma

Ronald Sanchez Avila and Jesus Merayo Lloves
University of Oviedo, Spain

Purpose: To evaluate the effectiveness that has the eye drops plasma rich in growth factors (PRGF) for the treatment of ocular surface diseases (OSD) in patients with glaucoma.

Material & Methods: Longitudinal, observational and descriptive study included 6 patients diagnosed with open-angle glaucoma who received surgical treatment (EPNP and or trabeculectomy) and medical (1-3 hypotensive eye drops) to control IOP (Intraocular pressure) which developed different ESD (Dry Eye Syndrome: Evaporative and or production shortfall, corneal ulcers, limbal stem cell deficiency, viral keratitis) unresponsive to conventional treatment. The variables analyzed were: VAS (Visual Analog Scale: Frequency and severity of symptoms), dry eye Psychometric Survey (OSDI: Ocular Surface Disease Index) Visual acuity (VA) far (LogMAR), tear breakup time (TBUT), Schirmer test and IOP; such measures were taken before starting treatment with PRGF, the next week, month and in subsequent visits, patients were followed for nearly a year.

Results: Patients was aged between 58 and 79 years (mean age, 71 ± 7.2). Treatment cycles with PRGF were between 2 and 6 (1 cycle=6 weeks). They target the AV (logMAR) improved 44.5% ($p=0.012$), the test OSDI decreased 58.5% ($p=0.027$), the VAS in frequency was decreased 53.5% ($p=0.026$), the VAS in severity decreased 44.57% ($p=0.027$) and IOP decreased by 16.5% ($p=0.010$); TBUT and Schirmer test improving trend was also evident. One patient reported itching in both eyes as a side effect (SE) but continued with the treatment until the end and the remaining patients reported no SE.

Conclusions: In patients with glaucoma and have ESD unresponsive to conventional treatments can now use the eye drops PRGF showing clinical improvement and reduction of IOP.

Biography

Ronald Sanchez Avila completed his training as a physician (National University of Colombia). He has completed Postgraduate studies in R&D of drugs, Health Management. Currently he is completing his training as an ophthalmologist at the Hospital Universitario Central de Asturias, and is a Doctoral candidate to the research of Ophthalmology and Vision Sciences (Univesidad of Oviedo, Eye Research Foundation, Ophthalmological Institute Fernandez-Vega). Results of his research have been presented at national and international congresses ophthalmology.

ronald.sanchezavila@gmail.com

Notes: